Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. STZ
4. PENG
5. NVDA
6. MSFT
7. LEVI
8. SPY
9. APLD
10. SKYD

Go back to Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune

AstraZeneca's (AZN) MedImmune to Acquire Inovio Pharma's (INO) NO-3112 Immunotherapy Rights

August 10, 2015 6:08 AM EDT

Inovio Pharma (NASDAQ: INO) announced that it has entered into a license agreement and collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN).

Under the agreement, MedImmune will acquire exclusive rights to Inovio's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for... More